IN2014MN01183A - - Google Patents

Info

Publication number
IN2014MN01183A
IN2014MN01183A IN1183MUN2014A IN2014MN01183A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A IN 1183MUN2014 A IN1183MUN2014 A IN 1183MUN2014A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A
Authority
IN
India
Prior art keywords
formula
heteromultimers
compounds
mediated
therapy
Prior art date
Application number
Other languages
English (en)
Inventor
David Madge
Fiona Chan
Derek Edward John
Simon D Edwards
Richard Blunt
Basil Hartzoulakis
Lindsay Brown
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1119703.5A external-priority patent/GB201119703D0/en
Priority claimed from GBGB1214250.1A external-priority patent/GB201214250D0/en
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of IN2014MN01183A publication Critical patent/IN2014MN01183A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1183MUN2014 2011-11-15 2012-11-15 IN2014MN01183A (en:Method)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1119703.5A GB201119703D0 (en) 2011-11-15 2011-11-15 Compounds
GBGB1214250.1A GB201214250D0 (en) 2012-08-09 2012-08-09 Compounds
PCT/GB2012/052842 WO2013072694A1 (en) 2011-11-15 2012-11-15 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN01183A true IN2014MN01183A (en:Method) 2015-07-03

Family

ID=47222145

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1183MUN2014 IN2014MN01183A (en:Method) 2011-11-15 2012-11-15

Country Status (15)

Country Link
US (2) US9290511B2 (en:Method)
EP (1) EP2780343A1 (en:Method)
JP (1) JP2014533259A (en:Method)
KR (1) KR20140094603A (en:Method)
CN (1) CN104011054B (en:Method)
AR (1) AR090037A1 (en:Method)
AU (1) AU2012338570A1 (en:Method)
BR (1) BR112014011671A2 (en:Method)
CA (1) CA2855346A1 (en:Method)
IN (1) IN2014MN01183A (en:Method)
MX (1) MX2014005935A (en:Method)
RU (1) RU2014124101A (en:Method)
TW (1) TWI498331B (en:Method)
WO (1) WO2013072694A1 (en:Method)
ZA (1) ZA201403503B (en:Method)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57250B1 (sr) 2013-06-06 2018-07-31 Astellas Pharma Inc Jedinjenje benzotiofena
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
RU2545758C1 (ru) * 2014-03-20 2015-04-10 Общество с ограниченной ответственностью "Алион" Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109311868B (zh) 2015-12-22 2022-04-01 尚医治疗有限责任公司 用于治疗癌症和炎性疾病的化合物
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
JP6919977B2 (ja) * 2016-03-16 2021-08-18 クラ オンコロジー，インク． メニン−ｍｌｌの置換された阻害剤及びその使用方法
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019034603A1 (en) * 2017-08-14 2019-02-21 Acesion Pharma Aps SUBSTITUTED BENZIMIDAZOLES USEFUL AS INHIBITORS OF THE POTASSIUM CHANNEL
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
AU2018373258B2 (en) 2017-11-27 2023-03-02 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
CN108117556A (zh) * 2018-01-15 2018-06-05 王山川 一种细胞周期检查点激酶1抑制剂的合成方法
EP3871673B1 (en) 2018-10-26 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
JP7458406B2 (ja) 2018-12-21 2024-03-29 セルジーン コーポレーション Ｒｉｐｋ２のチエノピリジン阻害剤
CR20220230A (es) 2019-10-28 2022-06-15 Merck Sharp & Dohme Inhibidores de pequeñas moléculas de mutante g12c de kras
WO2021106230A1 (ja) 2019-11-29 2021-06-03 大鵬薬品工業株式会社 新規なフェノール化合物又はその塩
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022194191A1 (en) * 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
EP4313973A1 (en) * 2021-03-22 2024-02-07 Acesion Pharma ApS Novel potassium channel inhibitors
TW202304925A (zh) * 2021-03-26 2023-02-01 美商住友製藥腫瘤公司 （呋喃并嘧啶—４—基）哌𠯤化合物及其用途
CN115006468B (zh) * 2022-06-28 2023-06-06 西安外事学院 一种复方中草药生发液及制备方法
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
CA2039411A1 (en) * 1990-03-30 1991-10-01 Ronnie Gerald Edie Thienopyrimidine derivatives
JP2001500482A (ja) 1996-08-27 2001-01-16 ノバルティス アクチェンゲゼルシャフト 除草性ｓ置換１，２，４，６―チアトリアジン類
WO2004011057A1 (en) 1998-02-07 2004-02-05 Advanced Cardiovascular Systems, Inc. Perfusion dilatation catherer with expanded support coil
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
AU766935B2 (en) 1999-09-17 2003-10-23 Nissan Chemical Industries Ltd. Benzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10031585A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
CZ20033469A3 (cs) 2001-06-25 2004-04-14 Nissan Chemical Industries, Ltd. Substituované benzopyranové deriváty proti arytmiím
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
JP2005508904A (ja) * 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
CN1823071B (zh) 2003-06-11 2012-12-19 润生有限公司 用作钾通道抑制剂的噻吩并嘧啶衍生物
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US7594219B2 (en) 2003-07-24 2009-09-22 International Business Machines Corporation Method and apparatus for monitoring compatibility of software combinations
TWI346112B (en) 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
US20070219234A1 (en) * 2004-04-12 2007-09-20 Kiyoshi Oizumi Thienopyridine Derivatives
CA2568304A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5122293B2 (ja) 2004-10-21 2013-01-16 ダウ アグロサイエンシィズ エルエルシー 殺真菌活性を有するチエノ−ピリミジン化合物
EP1879899B1 (en) 2004-12-09 2010-08-04 Xention Limited Thienopyridine derivatives as potassium channel inhibitors
US7576212B2 (en) * 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2595882A1 (en) 2005-01-26 2006-08-03 Pharmacia & Upjohn Company Llc Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
CA2602358A1 (en) 2005-03-25 2006-09-28 Pharmacia & Upjohn Company Llc 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2006103555A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2603041A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2006103545A1 (en) 2005-03-28 2006-10-05 Pharmacia & Upjohn Company Llc 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
US20060281768A1 (en) * 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
DE602005018972D1 (de) * 2005-09-23 2010-03-04 Equispharm Co Ltd 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0525164D0 (en) * 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
CA2654842A1 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
DE102006030236A1 (de) 2006-06-30 2008-01-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
CA2705719C (en) * 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
PT2254873E (pt) 2008-02-22 2014-08-29 Otsuka Pharma Co Ltd Compostos benzodiazepínicos e composições farmacêuticas que os contêm
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010023181A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TWI334124B (en) * 2008-08-28 2010-12-01 Au Optronics Corp Display drive circuit for flat panel display and driving method for gate lines
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
AR073739A1 (es) 2008-09-10 2010-12-01 Kalypsys Inc Aminopirimidinas como inhibidores de los receptores de histamina
WO2010033127A1 (en) 2008-09-22 2010-03-25 Sionyx, Inc. Response-enhanced monolithic-hybrid pixel
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2493892B1 (en) 2009-10-29 2015-07-01 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
KR20130005263A (ko) 2009-12-30 2013-01-15 아르퀼 인코포레이티드 치환된 나프탈레닐-피리미딘 화합물
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
CN103298460B (zh) 2010-12-14 2016-06-01 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
EP3239154A1 (en) 2011-01-10 2017-11-01 Nimbus Iris, Inc. Irak inhibitors and uses thereof

Also Published As

Publication number Publication date
US9290511B2 (en) 2016-03-22
EP2780343A1 (en) 2014-09-24
ZA201403503B (en) 2016-09-28
TWI498331B (zh) 2015-09-01
AR090037A1 (es) 2014-10-15
WO2013072694A1 (en) 2013-05-23
RU2014124101A (ru) 2015-12-27
US20140371203A1 (en) 2014-12-18
CA2855346A1 (en) 2013-05-23
US20160152634A1 (en) 2016-06-02
NZ626199A (en) 2015-04-24
BR112014011671A2 (pt) 2017-05-30
AU2012338570A1 (en) 2014-07-03
MX2014005935A (es) 2014-09-04
CN104011054A (zh) 2014-08-27
KR20140094603A (ko) 2014-07-30
CN104011054B (zh) 2016-08-24
JP2014533259A (ja) 2014-12-11
TW201326178A (zh) 2013-07-01

Similar Documents

Publication Publication Date Title
IN2014MN01183A (en:Method)
IN2012DN00971A (en:Method)
IN2014KN00769A (en:Method)
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
AU2012214029A8 (en) Rorgammat inhibitors
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
IN2014DN10670A (en:Method)
IN2014CN04907A (en:Method)
ZA201606320B (en) Human plasma kallikrein inhibitors
IN2014MN00988A (en:Method)
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
MY172924A (en) Neprilysin inhibitors
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
SG10201811204RA (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
UA118610C2 (uk) Спіроциклічні інгібітори катепсину c
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
IN2014CN04676A (en:Method)
IN2014MN00948A (en:Method)
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
GEP20135964B (en) Inhibitors of beta-secretase